Precision Medicine Initiatives

Many of the most serious human diseases have an origin, at least in part, in the genome. The ability to identify and characterize genomic changes underlying genetic-based diseases offers tremendous hope for transforming health care.

As part of Columbia University's overall Precision Medicine Initiative, IGM collaborates with clinical departments to provide a comprehensive interpretation of patient genomes and acts as a permanent resource for NewYork-Presbyterian clinicians to make effective use of genomic data to improve patient care.

The Precision Medicine Initiatives within IGM are managed collectively by Dr. David Goldstein and Vimla Aggarwal. To this end, IGM is targeting therapeutic areas where genomic data is expected to provide important clinical impact. These areas include:

  • Amyotrophic Lateral Sclerosis 
  • Anesthesiology and Pain
  • Epilepsy
  • Eye Diseases
  • Kidney & Liver Diseases
  • Maternal-Fetal Medicine
  • Undiagnosed Childhood Diseases
  • Osteoporosis
  • Hearing Loss
  • Pulmonary Disorders
  • Parkinson's Disease
  • OCD
  • IPF Lung Disease
  • Cardiogenetics
  • Nystagmus